{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T16:40:09Z","timestamp":1746290409178,"version":"3.40.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Gilead Sciences K.K."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>There is limited evidence on clinical outcomes and treatment pattern in Japanese patients with severe chronic kidney disease (CKD), hospitalized for coronavirus disease-2019 (COVID-19). We aimed to describe patient characteristics, treatment pattern, and clinical outcomes in Japanese patients with severe CKD, hospitalized for COVID-19 who received remdesivir (RDV).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We used the anonymized claims database from Medical Data Vision Co., Ltd., Japan. The analysis included patients aged\u2009\u2265\u200918\u00a0years with severe CKD, hospitalized for moderate to severe COVID-19, and administered\u2009\u2265\u20091 dose of RDV between October 2021 and September 2023. All-cause inpatient mortality, disease progression, and recovery up to 56\u00a0days from hospitalization were evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Data of 847 patients were analyzed (mean age 73.0\u2009\u00b1\u200914.1 years). Median (Q1\u2013Q3) time to RDV initiation was 1.0\u00a0day (1.0\u20132.0) from hospitalization and treatment duration was 5.0\u00a0days (3.0\u20135.0). At RDV initiation, 44.27% patients required non-invasive positive pressure ventilation\/high or low flow oxygen; 4.25% required invasive mechanical ventilation\/extracorporeal membrane oxygenation\/intensive care unit hospitalization. Proportion of patients with all-cause mortality was 11.45% (stage 4, 14.89%; stage 5, 10.47%) by 28 days and 12.28% (stage 4, 16.49%; stage 5, 11.08%) by 56 days. At 28 days, 12.28% had disease progression and 72.14% recovered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Most patients with severe CKD received RDV immediately after hospitalization. The majority of patients recovered by 28\u00a0days. The study provided insights into RDV treatment in inpatient settings, which could contribute to the discussion on standard of care in this population in Japan.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10157-024-02609-0","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T03:37:08Z","timestamp":1735529828000},"page":"624-637","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment pattern and clinical outcomes of remdesivir in hospitalized COVID-19 patients with severe chronic kidney disease: a database analysis of acute care hospitals in Japan"],"prefix":"10.1007","volume":"29","author":[{"given":"Manami","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Piao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikisha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Berry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jami","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazin","family":"Abdelghany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mel","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yotsuyanagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"2609_CR1","unstructured":"Ministry of Health, Labour and Welfare. Regarding the current situation of the new coronavirus infection and the response of the Ministry of Health, Labour and Welfare (February 4, 2020 edition; Japanese) 2020. https:\/\/www.mhlw.go.jp\/stf\/newpage_09290.html. Accessed 15 Dec 2023."},{"key":"2609_CR2","unstructured":"World Health Organization. COVID-19 advice for the public: getting vaccinated. 2023. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines\/advice. Accessed 16 Dec 2023."},{"key":"2609_CR3","unstructured":"Centers for Disease Control and Prevention. People with certain medical conditions. Updated 15 Apr 2024. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html. Accessed 16 Dec 2023."},{"key":"2609_CR4","unstructured":"British Columbia Centre for Disease Control. People with chronic conditions. Updated 20 Apr 2021. http:\/\/www.bccdc.ca\/health-info\/diseases-conditions\/covid-19\/priority-populations\/people-with-chronic-conditions. Accessed 16 Dec 2023."},{"key":"2609_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40620-021-01206-8","volume":"35","author":"SS Jdiaa","year":"2022","unstructured":"Jdiaa SS, Mansour R, El Alayli A, Gautam A, Thomas P, Mustafa RA. COVID\u201319 and chronic kidney disease: an updated overview of reviews. J Nephrol. 2022;35:69\u201385.","journal-title":"J Nephrol"},{"key":"2609_CR6","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.10.020503","volume":"10","author":"MMA Khan","year":"2020","unstructured":"Khan MMA, Khan MN, Mustagir MG, Rana J, Islam MS, Kabir MI. Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: a systematic review and meta-analysis. J Glob Health. 2020;10: 020503.","journal-title":"J Glob Health"},{"key":"2609_CR7","doi-asserted-by":"publisher","first-page":"E66","DOI":"10.5888\/pcd18.210123","volume":"18","author":"L Kompaniyets","year":"2021","unstructured":"Kompaniyets L, Pennington AF, Goodman AB, Rosenblum HG, Belay B, Ko JY, et al. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020\u2013March 2021. Prev Chronic Dis. 2021;18:E66.","journal-title":"Prev Chronic Dis"},{"key":"2609_CR8","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.kint.2020.09.006","volume":"98","author":"KJ Jager","year":"2020","unstructured":"Jager KJ, Kramer A, Chesnaye NC, Couchoud C, S\u00e1nchez-\u00c1lvarez JE, Garneata L, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020;98:1540\u20138.","journal-title":"Kidney Int"},{"key":"2609_CR9","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s10157-021-02082-z","volume":"25","author":"Y Sugawara","year":"2021","unstructured":"Sugawara Y, Iwagami M, Yoshida Y, Kikuchi K, Ando R, Shinoda T, et al. Nationwide survey of the coronavirus disease 2019 prevention and treatment systems for kidney disease patients: a study of Japanese Society of Nephrology-certified educational facilities. Clin Exp Nephrol. 2021;25:996\u20131002.","journal-title":"Clin Exp Nephrol"},{"key":"2609_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/1744-9987.13531","volume":"24","author":"K Kikuchi","year":"2020","unstructured":"Kikuchi K, Nangaku M, Ryuzaki M, Yamakawa T, Hanafusa N, Sakai K, et al. COVID-19 of dialysis patients in Japan: current status and guidance on preventive measures. Ther Apher Dial. 2020;24:361\u20135.","journal-title":"Ther Apher Dial"},{"key":"2609_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s41100-021-00378-0","volume":"7","author":"K Kikuchi","year":"2021","unstructured":"Kikuchi K, Nangaku M, Ryuzaki M, Yamakawa T, Yoshihiro O, Hanafusa N, et al. Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study. Ren Replace Ther. 2021;7:59.","journal-title":"Ren Replace Ther"},{"key":"2609_CR12","unstructured":"National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2021. https:\/\/www.covid19treatmentguidelines.nih.gov\/. Accessed 16 Dec 2023."},{"key":"2609_CR13","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/17512433.2020.1821650","volume":"13","author":"A Saint-Raymond","year":"2020","unstructured":"Saint-Raymond A, Sato J, Kishioka Y, Teixeira T, Hasslboeck C, Kweder SL. Remdesivir emergency approvals: a comparison of the U.S., Japanese, and EU systems. Expert Rev Clin Pharmacol. 2020;13:1095\u2013101.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2609_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/ams2.789","volume":"9","author":"K Yamakawa","year":"2022","unstructured":"Yamakawa K, Yamamoto R, Terayama T, Hashimoto H, Ishihara T, Ishimaru G, et al. Japanese rapid\/living recommendations on drug management for COVID-19: updated guidelines (July 2022). Acute Med Surg. 2022;9: e789. https:\/\/doi.org\/10.1002\/ams2.789.","journal-title":"Acute Med Surg"},{"key":"2609_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3379","volume":"370","author":"A Agarwal","year":"2020","unstructured":"Agarwal A, Hunt B, Stegemann M, Rochwerg B, Lamontagne F, Siemieniuk RA, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370: m3379.","journal-title":"BMJ"},{"key":"2609_CR16","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jama.2020.16349","volume":"324","author":"CD Spinner","year":"2020","unstructured":"Spinner CD, Gottlieb RL, Criner GJ, Arribas L\u00f3pez JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324:1048\u201357.","journal-title":"JAMA"},{"key":"2609_CR17","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19\u2014final report. N Engl J Med. 2020;383:1813\u201326.","journal-title":"N Engl J Med"},{"key":"2609_CR18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","volume":"386","author":"RL Gottlieb","year":"2022","unstructured":"Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386:305\u201315.","journal-title":"N Engl J Med"},{"key":"2609_CR19","unstructured":"Santos JR, Goldman JD, Tuttle KR, Teixeira JP, Koullias Y, Llewellyn J, et al. The REDPINE study: efficacy and safety of remdesivir in people with moderately and severely reduced kidney function hospitalised for COVID-19 pneumonia. Poster presented at the 23rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID); 15\u201318 April 2023;P2635."},{"key":"2609_CR20","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.3390\/healthcare10112299","volume":"10","author":"T Umemura","year":"2022","unstructured":"Umemura T, Mutoh Y, Mizuno T, Hagihara M, Kato H, Yamada T, et al. Safety evaluation of remdesivir for COVID-19 patients with eGFR < 30\u00a0mL\/min without renal replacement therapy in a Japanese single-center study. Healthcare (Basel). 2022;10:2299.","journal-title":"Healthcare (Basel)"},{"key":"2609_CR21","unstructured":"Medical Data Vision. 2024 Japan. https:\/\/en.mdv.co.jp\/ebm\/. Accessed 26 Feb 2024."},{"key":"2609_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40801-022-00296-5","volume":"9","author":"T Laurent","year":"2022","unstructured":"Laurent T, Simeone J, Kuwatsuru R, Hirano T, Graham S, Wakabayashi R, et al. Context and considerations for use of two Japanese real-world databases in Japan: Medical Data Vision and Japanese Medical Data Center. Drugs Real World Outcomes. 2022;9:175\u201387.","journal-title":"Drugs Real World Outcomes"},{"key":"2609_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41100-022-00405-8","volume":"8","author":"A Yoshifuji","year":"2022","unstructured":"Yoshifuji A, Ryuzaki M, Uehara Y, Ohmagari N, Kawai T, Kanno Y, et al. Committee report: questionnaire survey on the treatment of COVID-19 in patients receiving dialysis therapy. Ren Replace Ther. 2022;8:18.","journal-title":"Ren Replace Ther"},{"key":"2609_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.37737\/ace.23009","volume":"5","author":"S Hamaguchi","year":"2023","unstructured":"Hamaguchi S, Watanabe A, Nakamoto Y, Aita T, Naganuma T, Takahashi S, et al. Antiviral medications for mild-to-moderate COVID-19 in Japan: a gap of timing between clinical trials and real-world scenarios in a fast-changing pandemic. Ann Clin Epidemiol. 2023;5:65\u201373.","journal-title":"Ann Clin Epidemiol"},{"key":"2609_CR25","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1093\/cid\/ciab1035","volume":"75","author":"BT Garibaldi","year":"2022","unstructured":"Garibaldi BT, Wang K, Robinson ML, Betz J, Caleb Alexander G, Andersen KM, et al. Real-world effectiveness of remdesivir in adults hospitalized with coronavirus disease 2019 (COVID-19): a retrospective, multicenter comparative effectiveness study. Clin Infect Dis. 2022;75:e516\u201324.","journal-title":"Clin Infect Dis"},{"key":"2609_CR26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.resinv.2023.12.016","volume":"62","author":"J Peters","year":"2024","unstructured":"Peters J, Force L, Ng LJ, Li H, Aoki K, Taguchi N, et al. The safety and effectiveness of remdesivir in a postmarketing surveillance study in Japan. Respir Investig. 2024;62:192\u20139.","journal-title":"Respir Investig"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-024-02609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-024-02609-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-024-02609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T16:02:52Z","timestamp":1746288172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-024-02609-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2609"],"URL":"https:\/\/doi.org\/10.1007\/s10157-024-02609-0","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"type":"print","value":"1342-1751"},{"type":"electronic","value":"1437-7799"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects do not apply to studies of secondary analyses using anonymized data, review of an institutional review board\/research ethics committee was not required. No informed consent was obtained from patients to participate in this secondary analysis of existing anonymized data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"MY, NT, YP, RG, MB, JP, MA, MC, and C-YW are employees of Gilead Sciences. HY received lecture fees from Gilead Sciences K. K. NT, YP, MB, and MA have stock ownership for Gilead Sciences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}